頭蓋内動脈瘤治療のための Silk Vista および Silk Vista Baby Flow Diverter の安全性と有効性 (FIRST)
頭蓋内動脈瘤治療のための Silk Vista および Silk Vista Baby Flow Diverter の安全性と有効性、観察的、前向き、単一アーム、国際、多施設研究。
The FIRST study is an observational, prospective, multi-center, international, single-arm, study. The aim of the study is to collect safety and efficacy information on the use of the silk vista and silk vista baby flow diverter in order to assess clinical safety and performance of the device for treating intracranial aneurysms.
All patients with intracranial aneurysm ruptured or unruptured, whatever the localization of the aneurysm, and treated with silk vista or silk vista baby, will be consecutively enrolled in the study.
The patient's inclusion and follow up in the study will occur as part of their usual standard of care.
調査の概要
状態
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
-
Jerusalem、イスラエル、9112001
- Hadassah Medical Center
-
Nahariya、イスラエル、22100
- Galilee Medical Center
-
-
-
-
-
Milan、イタリア、20162
- Niguarda Hospital
-
Monza、イタリア、20900
- San Gerardo Hospital
-
Treviso、イタリア、31100
- Cà Foncello Hospital
-
Udine、イタリア、33100
- Santa maria della misericordia hospital
-
-
-
-
-
Nijmegen、オランダ、6525 G
- Radboud University medical Center
-
-
-
-
-
Salzburg、オーストリア、A-5020
- Universitätsklinik für Neurologie
-
-
-
-
-
Zagreb、クロアチア、10000
- University Hospital Centre Zagreb
-
-
-
-
-
Barakaldo、スペイン、48903
- Hospital Universitario de cruces
-
Madrid、スペイン、28222
- Hopsital universidad puerta de hierro
-
Madrid、スペイン、28034
- Ramon y Cajal hospital
-
Oviedo、スペイン、33011
- Unversitario Central de Asturias
-
Valladolid、スペイン、47003
- Hospital Clinico Universitario de Valladolid
-
-
-
-
-
München、ドイツ、81377
- Munich LMU University
-
-
-
-
-
Bordeaux、フランス、33000
- CHU de Bordeaux - Hôpital Pellegrin
-
Brest、フランス、29200
- Hopital Cavale Blanche
-
Bron、フランス、69677
- Hospices Civils de Lyon - Hôpital Neurologique
-
Caen、フランス、14033
- CHU Caen, Radiologie interventionelle
-
Clermont-Ferrand、フランス、63003
- Centre Hospitalier Universitaire Clermont Ferrand
-
Grenoble、フランス、38043
- Centre Hospitalier Universitaire de Grenoble Alpes
-
Le Kremlin-Bicêtre、フランス、94270
- Hôpital Kremlin Bicêtre
-
Limoges、フランス、87000
- Chu Dupuytren Limoges
-
Marseille、フランス、13009
- Hôpital Privé Clairval
-
Paris、フランス、75651
- Pitié-Salpêtrière Hospital
-
Paris、フランス、75019
- Fondation Rothschild
-
Rouen、フランス、76000
- CHU Chalre Nicolle
-
Tours、フランス、37044
- Centre Hospitalier Régional Universitaire de Tours
-
-
-
-
-
Liège、ベルギー、4000
- CHC Saint Joseph Liège
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients with an intracranial aneurysm treated with silk vista and silk vista baby.
説明
Inclusion Criteria:
- Patient with intracranial aneurysms intended to be treated with the silk vista and silk vista baby (decision of use silk vista and silk vista baby is done independently and prior to the participation of the patient in the study)
- Patients with recanalized aneurysms previously treated with coils exclusively are also eligible.
- In case of multiple aneurysms, only treatment with silk vista and silk vista baby are allowed (between the initial index procedure to the 12 months follow up visit)
- Patient ≥ 18 years, who signed an informed consent.
Exclusion Criteria:
- Patient presenting with contra-indications to the use of silk vista and silk vista babyaccording to the IFU (Instruction for Use).
- Recanalized aneurysms initially treated with stent (including stent assisted coiling)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.
時間枠:At 12-months (-3 / + 6 months) post procedure
|
Characterized by the rate of the permanent neurologic deficits and procedure related mortality. |
At 12-months (-3 / + 6 months) post procedure
|
|
Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.
時間枠:At 12-months (-3 / + 6 months) post procedure
|
Characterized by the clinical outcome assessed by mRS of the permanent neurologic deficits and procedure related mortality. |
At 12-months (-3 / + 6 months) post procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety of silk vista and silk vista baby
時間枠:At T0
|
Assessed by the rate of adverse events |
At T0
|
|
Safety of silk vista and silk vista baby
時間枠:At hospital discharge
|
Assessed by the rate of adverse events |
At hospital discharge
|
|
Safety of silk vista and silk vista baby
時間枠:Up to 30 days (-10 / + 21 days) post- procedure.
|
Assessed by the rate of adverse events |
Up to 30 days (-10 / + 21 days) post- procedure.
|
|
Safety of silk vista and silk vista baby
時間枠:At 6 months (-2/+3 months) post- procedure.
|
Assessed by the rate of adverse events |
At 6 months (-2/+3 months) post- procedure.
|
|
Safety of silk vista and silk vista baby
時間枠:At 12 months (-3/+6 months) post- procedure.
|
Assessed by the rate of adverse events |
At 12 months (-3/+6 months) post- procedure.
|
|
Safety of silk vista and silk vista baby
時間枠:At 3 years post procedure
|
Assessed by the rate of adverse events |
At 3 years post procedure
|
|
Safety of silk vista and silk vista baby
時間枠:At 5 years post procedure
|
Assessed by the rate of adverse events |
At 5 years post procedure
|
|
Efficacy of silk vista and silk vista baby
時間枠:At T0
|
Assessed by aneurysm occlusion rate |
At T0
|
|
Efficacy of silk vista and silk vista baby
時間枠:At hospital discharge
|
Assessed by aneurysm occlusion rate |
At hospital discharge
|
|
Efficacy of silk vista and silk vista baby
時間枠:Up to 30 days (-10 / + 21 days) post- procedure.
|
Assessed by aneurysm occlusion rate |
Up to 30 days (-10 / + 21 days) post- procedure.
|
|
Efficacy of silk vista and silk vista baby
時間枠:Up to 6 months (-2/+3 months) post- procedure
|
Assessed by aneurysm occlusion rate |
Up to 6 months (-2/+3 months) post- procedure
|
|
Efficacy of silk vista and silk vista baby
時間枠:Up to 12 months (-3 / + 6 months) post procedure
|
Assessed by aneurysm occlusion rate |
Up to 12 months (-3 / + 6 months) post procedure
|
|
Efficacy of silk vista and silk vista baby
時間枠:Up to 3 years post procedure
|
Assessed by aneurysm occlusion rate |
Up to 3 years post procedure
|
|
Efficacy of silk vista and silk vista baby
時間枠:Up to 5 years post procedure
|
Assessed by aneurysm occlusion rate |
Up to 5 years post procedure
|
|
Technical procedure
時間枠:At T0
|
The practices related to the use of silk vista baby will be describe |
At T0
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Mario Martinez Galdamez, Dr、Hospital Clinico Universitario de Valladolid (HCUV), Spain
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。